In addition, the results suggested that the PAR-2 agonists activated and upregulated PAR-2 levels, thus promoting cancer cell proliferation, suggesting that PAR-2 activation may be crucial in the development of pancreatic cancer. Here, F2RL1 is linked to familial pancreatic carcinoma.